Answers are grounded in this paper and cite their sources.
Influenza B/Yamagata viruses have not been detected globally since 2020 and were removed from U.S. 2024/25 seasonal influenza vaccines. We inferred impacts of vaccination against B/Yamagata from 2016/17–2019/20 by combining B/Yamagata prevalence data with model-based estimates of disease burden prevented by vaccination against all influenza B viruses. B/Yamagata comprised approximately 16–22% of U.S. positive virus specimens in 2016/17 and 2017/18, compared to 1% in 2018/19 and 2019/20. Across all seasons, we estimated that vaccination against B/Yamagata prevented 4.15 million symptomatic illnesses, 58,500 hospitalizations, and 4070 deaths, and that 22.9 million B/Yamagata-associated symptomatic illnesses, 340,000 hospitalizations, and 25,100 deaths would have occurred without vaccination. Vaccination prevented the most B/Yamagata hospitalizations among adults ≥65 years but prevented the greatest percentage of B/Yamagata hospitalizations among children 6 months–4 years. Our results may help assess the potential impact if B/Yamagata were to recirculate in the absence of vaccination.
No takes yet. Share an insight, caveat, or question.
Morris et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: